Document Detail

VSV oncolysis in combination with the BCL-2 inhibitor obatoclax overcomes apoptosis resistance in chronic lymphocytic leukemia.
MedLine Citation:
PMID:  20842105     Owner:  NLM     Status:  MEDLINE    
In chronic lymphocytic leukemia (CLL), overexpression of antiapoptotic B-cell leukemia/lymphoma 2 (BCL-2) family members contributes to leukemogenesis by interfering with apoptosis; BCL-2 expression also impairs vesicular stomatitis virus (VSV)-mediated oncolysis of primary CLL cells. In the effort to reverse resistance to VSV-mediated oncolysis, we combined VSV with obatoclax (GX15-070)-a small-molecule BCL-2 inhibitor currently in phase 2 clinical trials-and examined the molecular mechanisms governing the in vitro and in vivo antitumor efficiency of combining the two agents. In combination with VSV, obatoclax synergistically induced cell death in primary CLL samples and reduced tumor growth in severe combined immunodeficient (SCID) mice-bearing A20 lymphoma tumors. Mechanistically, the combination stimulated the mitochondrial apoptotic pathway, as reflected by caspase-3 and -9 cleavage, cytochrome c release and BAX translocation. Combination treatment triggered the release of BAX from BCL-2 and myeloid cell leukemia-1 (MCL-1) from BAK, whereas VSV infection induced NOXA expression and increased the formation of a novel BAX-NOXA heterodimer. Finally, NOXA was identified as an important inducer of VSV-obatoclax driven apoptosis via knockdown and overexpression of NOXA. These studies offer insight into the synergy between small-molecule BCL-2 inhibitors such as obatoclax and VSV as a combination strategy to overcome apoptosis resistance in CLL.
Sara Samuel; Vanessa F Tumilasci; Stephanie Oliere; Thi Liên-Anh Nguyên; April Shamy; John Bell; John Hiscott
Related Documents :
13678665 - Targeted expression of bcl-2 attenuates mpp+ but not 6-ohda induced cell death in dopam...
15590405 - Altered apoptosis and cell cycling of mast cells in bone marrow lesions of patients wit...
20842105 - Vsv oncolysis in combination with the bcl-2 inhibitor obatoclax overcomes apoptosis res...
9267815 - Apoptosis in human endometrial and endometriotic tissues.
24623145 - Endogenous tim-1 promotes severe systemic autoimmunity and renal disease mrl-fas{uparro...
20476975 - Interactions of fox proteins with inflammatory transcription-factor pathways.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2010-09-14
Journal Detail:
Title:  Molecular therapy : the journal of the American Society of Gene Therapy     Volume:  18     ISSN:  1525-0024     ISO Abbreviation:  Mol. Ther.     Publication Date:  2010 Dec 
Date Detail:
Created Date:  2010-12-01     Completed Date:  2011-04-18     Revised Date:  2013-05-27    
Medline Journal Info:
Nlm Unique ID:  100890581     Medline TA:  Mol Ther     Country:  United States    
Other Details:
Languages:  eng     Pagination:  2094-103     Citation Subset:  IM    
Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Quebec, Canada.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antineoplastic Agents / pharmacology
Cell Line, Tumor
Combined Modality Therapy
Disease Models, Animal
Genetic Therapy
Leukemia, Lymphocytic, Chronic, B-Cell / therapy*
Mice, SCID
Proto-Oncogene Proteins c-bcl-2 / antagonists & inhibitors*
Pyrroles / pharmacology*
Reverse Transcriptase Polymerase Chain Reaction
Vesiculovirus* / physiology
Grant Support
//Canadian Institutes of Health Research
Reg. No./Substance:
0/Antineoplastic Agents; 0/Proto-Oncogene Proteins c-bcl-2; 0/Pyrroles; 0/obatoclax

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Paracrine factors of multipotent stromal cells ameliorate lung injury in an elastase-induced emphyse...
Next Document:  T cells expressing constitutively active Akt resist multiple tumor-associated inhibitory mechanisms.